Applying stem cell technology for cardiovascular indications is not just an idea anymore.
CardioCell is currently in clinical trials using stem cells to develop “off-the-shelf” products for cardiovascular indication. The company is exploring unmet medical needs in:
- Acute Myocardial Infarction (AMI)
- Chronic Heart Failure (CHF)
- Peripheral Artery Disease (PAD)
For clinical trials, CardioCell is using cGMP allogeneic stem cells derived from the bone marrow of healthy volunteers. These cells are manufactured in a licensed cGMP-compliant facility.